Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
H02 CORTICOSTEROIDS FOR SYSTEMIC USE
H02C ANTIADRENAL PREPARATIONS
H02CA Anticorticosteroids
H02CA02 Osilodrostat
D11062 Osilodrostat phosphate (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Hormonal Agents, Suppressant (Pituitary)
Osilodrostat
D11062 Osilodrostat phosphate (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
24 Hormones
249 Miscellaneous
2499 Others
D11062 Osilodrostat phosphate (JAN/USAN)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG02919 CYP2B6 substrate
DG02839 Osilodrostat
D11062 Osilodrostat phosphate
DG01644 CYP2D6 substrate
DG02839 Osilodrostat
D11062 Osilodrostat phosphate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG02839 Osilodrostat
D11062 Osilodrostat phosphate
DG02924 UGT substrate
DG02839 Osilodrostat
D11062 Osilodrostat phosphate
Target-based classification of drugs [BR:br08310]
Enzymes
Oxidoreductases (EC1)
Cytochrome P450
CYP11B2
D11062 Osilodrostat phosphate (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11062
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11062
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11062
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11062
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11062
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG02919 CYP2B6 substrate
DG02839 Osilodrostat
DG01644 CYP2D6 substrate
DG02839 Osilodrostat
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG02839 Osilodrostat
DG02924 UGT substrate
DG02839 Osilodrostat